TIMOTHY FORD: Open Payments
NPI 1053718197 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$807 in 35 payments from 12 companies in 2025. Trend: 2023 $562 · 2024 $1,434 · 2025 $807
Food & beverage: $807
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $215 |
| Otsuka America Pharmaceutical, Inc. | 8 | $162 |
| Neurocrine BioSciences, Inc. | 4 | $111 |
| Teva Pharmaceuticals USA, Inc. | 4 | $88 |
| E.R. Squibb & Sons, L.L.C. | 2 | $56 |
| Tris Pharma Inc | 2 | $51 |
| Janssen Pharmaceuticals, Inc | 1 | $26 |
| Alkermes, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Luye Pharma (USA) Ltd. | 1 | $21 |
Products named: CAPLYTA, INGREZZA, REXULTI, UZEDY, COBENFY, Onyda XR, ABILIFY ASIMTUFII, INVEGA SUSTENNA.
Industry payments across TX — which companies pay providers there.
